Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement

J. M. Orengo (), A. R. Radin, V. Kamat, A. Badithe, L. H. Ben, B. L. Bennett, S. Zhong, D. Birchard, A. Limnander, A. Rafique, J. Bautista, A. Kostic, D. Newell, X. Duan, M. C. Franklin, W. Olson, T. Huang, N. A. Gandhi, L. Lipsich, N. Stahl, N. J. Papadopoulos, A. J. Murphy and G. D. Yancopoulos
Additional contact information
J. M. Orengo: Regeneron Pharmaceuticals Inc.
A. R. Radin: Regeneron Pharmaceuticals Inc.
V. Kamat: Regeneron Pharmaceuticals Inc.
A. Badithe: Regeneron Pharmaceuticals Inc.
L. H. Ben: Regeneron Pharmaceuticals Inc.
B. L. Bennett: Regeneron Pharmaceuticals Inc.
S. Zhong: Regeneron Pharmaceuticals Inc.
D. Birchard: Regeneron Pharmaceuticals Inc.
A. Limnander: Regeneron Pharmaceuticals Inc.
A. Rafique: Regeneron Pharmaceuticals Inc.
J. Bautista: Regeneron Pharmaceuticals Inc.
A. Kostic: Regeneron Pharmaceuticals Inc.
D. Newell: Regeneron Pharmaceuticals Inc.
X. Duan: Regeneron Pharmaceuticals Inc.
M. C. Franklin: Regeneron Pharmaceuticals Inc.
W. Olson: Regeneron Pharmaceuticals Inc.
T. Huang: Regeneron Pharmaceuticals Inc.
N. A. Gandhi: Regeneron Pharmaceuticals Inc.
L. Lipsich: Regeneron Pharmaceuticals Inc.
N. Stahl: Regeneron Pharmaceuticals Inc.
N. J. Papadopoulos: Regeneron Pharmaceuticals Inc.
A. J. Murphy: Regeneron Pharmaceuticals Inc.
G. D. Yancopoulos: Regeneron Pharmaceuticals Inc.

Nature Communications, 2018, vol. 9, issue 1, 1-15

Abstract: Abstract Acute allergic symptoms are caused by allergen-induced crosslinking of allergen-specific immunoglobulin E (IgE) bound to Fc-epsilon receptors on effector cells. Desensitization with allergen-specific immunotherapy (SIT) has been used for over a century, but the dominant protective mechanism remains unclear. One consistent observation is increased allergen-specific IgG, thought to competitively block allergen binding to IgE. Here we show that the blocking potency of the IgG response to Cat-SIT is heterogeneous. Next, using two potent, pre-selected allergen-blocking monoclonal IgG antibodies against the immunodominant cat allergen Fel d 1, we demonstrate that increasing the IgG/IgE ratio reduces the allergic response in mice and in cat-allergic patients: a single dose of blocking IgG reduces clinical symptoms in response to nasal provocation (ANCOVA, p = 0.0003), with a magnitude observed at day 8 similar to that reported with years of conventional SIT. This study suggests that simply augmenting the blocking IgG/IgE ratio may reverse allergy.

Date: 2018
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-018-03636-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-03636-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-03636-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().